Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sawai Group Holdings CoSWGHF 53 EV-to-EBITDA is 7.84 as of Aug. 04, 2026, which is 5% below its 10-year median of 8.26. GuruFocus rates SWGHF with a GF Score™ of 53/100 and a GF Value™ of $15.98. The stock has 3 warning signs investors should review. Among 746 Drug Manufacturers companies, Sawai Group Holdings Co ranks better than 70.11% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sawai Group Holdings Co's enterprise value is $1,666 Mil.
Sawai Group Holdings Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $212 Mil. Therefore, Sawai Group Holdings Co's EV-to-EBITDA for today is 7.84.
The historical rank and industry rank for Sawai Group Holdings Co's EV-to-EBITDA or its related term are showing as below:
SWGHF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.06 Med: 8.26 Max: 24.92
Current: 8.34
During the past 5 years, the highest EV-to-EBITDA of Sawai Group Holdings Co was 24.92. The lowest was -12.06. And the median was 8.26.
SWGHF's EV-to-EBITDA is ranked better than 70.11% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.08
vs SWGHF: 8.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sawai Group Holdings Co (OTCPK:SWGHF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sawai Group Holdings Co's PE Ratio (TTM) for today is calculated as:
Sawai Group Holdings Co's share price for today is $11.52.
Sawai Group Holdings Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.602.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sawai Group Holdings Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sawai Group Holdings Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sawai Group Holdings Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sawai Group Holdings Co's EV-to-EBITDA falls into.
Sawai Group Holdings Co's current Enterprise Value is $1,666 Mil.
Sawai Group Holdings Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $212 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sawai Group Holdings Co (SWGHF) has a EV-to-EBITDA of 7.84 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sawai Group Holdings Co. This is near median its historical median of 8.26. According to the industry distribution chart, Sawai Group Holdings Co ranks #223 out of 746 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is Sawai Group Holdings Co's EV-to-EBITDA too high?
Sawai Group Holdings Co's current EV-to-EBITDA of 7.84 is near median its 10-year median of 8.26. The Drug Manufacturers industry median EV-to-EBITDA is 13.08. Sawai Group Holdings Co's value of 7.84 is 40.1% below this industry median. Based on the distribution chart, Sawai Group Holdings Co ranks #223 out of 746 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sawai Group Holdings Co has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Sawai Group Holdings Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sawai Group Holdings Co ranks #223 out of 746 companies for EV-to-EBITDA. This puts Sawai Group Holdings Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.08. Sawai Group Holdings Co's value of 7.84 is 40.1% below this benchmark. While the company's 10-year median is 8.26 vs. the industry median of 13.08, Sawai Group Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.08, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sawai Group Holdings Co's current EV-to-EBITDA of 7.84 is 40.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sawai Group Holdings Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sawai Group Holdings Co's current EV-to-EBITDA is 7.84, which is near median its own 10-year median of 8.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sawai Group Holdings Co stock overvalued right now?
Sawai Group Holdings Co (SWGHF) has a current EV-to-EBITDA of 7.84. The stock's GF Value™ is $15.98, compared to a current price of $11.52 — trading 27.9% below its estimated fair value. The current EV-to-EBITDA is 7.84, which is near median its 10-year median of 8.26 and 40.1% below the Drug Manufacturers industry median of 13.08. Sawai Group Holdings Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sawai Group Holdings Co (SWGHF), the current EV-to-EBITDA is 7.84 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sawai Group Holdings Co (SWGHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sawai Group Holdings Co stock appears to be undervalued.
The current stock price of $11.52 is trading 27.9% below its estimated GF Value™ of $15.98.
Key valuation signals for SWGHF:
EV-to-EBITDA: 7.84 (near median its 10-year median of 8.26)
GF Value™: $15.98 vs. price of $11.52 (27.9% below fair value)
Industry Position: 40.1% below the Drug Manufacturers median (#223 of 746)
No single metric tells the full story. See the SWGHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sawai Group Holdings Co Ltd is engaged in providing management support or guidance to domestic and foreign companies engaged in businesses related to medical and healthcare services, such as the manufacture and sale of pharmaceutical products and medical equipment, as well as various businesses incidental or related to the same.
53GF Score
Get the complete analysis for SWGHF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWGHF has been successfully added to your 
